=== LAI DOMAIN SCORING PROMPT v3.0 ===
Generated: 2026-02-05 11:00:45
Sources: technology_scopes.yaml, trademark_scopes.yaml, exclusion_scopes.yaml

MISSION:
Evaluate if a pharma/biotech news item is relevant to Long-Acting Injectables (LAI).
Return: is_relevant (bool), score (0-100), reasoning (string).

DEFINITION LAI:
Injectable pharmaceutical formulations providing sustained drug release over weeks to months 
after a single injection. Improves patient adherence and therapeutic outcomes.

Key characteristics:
- Extended release: weeks to months duration
- Injectable routes: SC, IM, intravitreal, intratumoral
- Technologies: microspheres, depots, hydrogels, PEGylation, Fc fusion
- Dosing: weekly, monthly, quarterly, semi-annual

MATCHING LOGIC (simplified - NO company type distinction):

1. STRONG SIGNALS (1+ detected = relevant)
   - Core LAI terms: long-acting injectable, long acting injectable, long-acting formulation... [13 total]
   - LAI trademarks: Plenaxis, Idelvion, Aristada... [76 total]

2. MEDIUM SIGNALS (2+ detected = relevant)
   - Technology families: drug delivery system, drug delivery, controlled release... [56 total]
   - Dosing intervals: once-monthly, once-weekly injection, once every 2 weeks... [14 total]

3. EXCLUSIONS (1+ detected = reject)
   - Anti-LAI terms: implantable device, surgically implanted, transdermal patch... [21 total]

SCORING RULES:
- Base score by event_type:
  * partnership: 60
  * regulatory: 70
  * clinical_update: 50
  * corporate_move: 40
  * financial_results: 0 (only score if 2+ LAI signals)
  * other: 20

- Entity boosts:
  * +20 if trademark detected
  * +15 if dosing_interval detected
  * +10 if technology_family detected

- Recency boost:
  * +10 if item < 7 days old
  * +5 if item < 30 days old

- Threshold: score >= 50 = relevant

CRITICAL RULES:
1. IGNORE company type (pure_player vs hybrid) - focus ONLY on LAI signals
2. Manufacturing news WITHOUT LAI technology → REJECT
3. Financial results WITHOUT 2+ LAI signals → REJECT
4. Be conservative: when in doubt, REJECT
5. Only detect signals EXPLICITLY present in the item data

OUTPUT FORMAT (JSON only, no additional text):
{
  "is_relevant": true,
  "score": 75,
  "reasoning": "Trademark UZEDY detected + microsphere technology + partnership event"
}

If NOT relevant:
{
  "is_relevant": false,
  "score": 0,
  "reasoning": "Exclusion detected: oral tablet. Not LAI-relevant."
}

=== FULL TERM LISTS ===

[CORE LAI TERMS - 13 terms]
- long-acting injectable
- long acting injectable
- long-acting formulation
- extended-release injection
- extended-release injectable
- controlled-release injection
- injectable controlled release
- sustained release injectable
- sustained-release injectable
- depot injection
- long-acting depot
- long-acting
- long acting

[LAI TRADEMARKS - 76 terms]
- Plenaxis
- Idelvion
- Aristada
- Abilify Maintena
- Abilify Asimtufi
- Posimir
- Exparel
- Zynrelef
- Brixadi
- Sublocade
- Apretude
- Cabenuva
- Cetrotide
- Acthar Gel
- DepoCyt
- Firmagon
- ALTUVIIIO
- Elocta
- Parsabiv
- Faslodex
- ZOLADEX
- Sustol
- Tresiba
- Levemir
- Lantus
- Somatuline
- Sunlenca
- LUTRATE DEPOT
- Lupron depot
- CAMCEVI
- Skytrofa
- Depo provera
- Mircera
- Depodur
- Vivitrol
- Sandostatin
- Zyprexa Relprevv
- Invega trinza
- Signifor
- Somavert
- REZZAYO
- Risperdal Consta
- Uzedy
- UZEDY
- UZEDY®
- Rykindo
- Besremi
- Adynovate
- Enspryng
- Ozempic
- Sogroya
- NGENLA
- Aveed
- Zilretta
- TRELSTAR
- Esperoct
- BYDUREON
- IMCIVREE
- Aranesp
- PEGASYS
- Jivi
- JELMYTO
- Perseris
- DAXXIFY
- WEGOVY
- Erzofri
- Victoza
- Trulicity
- Mounjaro
- Soliqua
- PharmaShell®
- PharmaShell
- BEPO®
- BEPO
- SiliaShell®
- SiliaShell Oclaiz

[TECHNOLOGY FAMILIES - 56 terms]
- drug delivery system
- drug delivery
- controlled release
- sustained release
- extended release
- modified release
- PharmaShell®
- PharmaShell
- Pharmashell
- pharma shell
- SiliaShell®
- BEPO®
- extended-release injectable
- long-acting injectable
- LAI
- depot injection
- once-monthly injection
- atomic layer deposition
- Half life extension
- half life extended
- polymeric microspheres
- PLGA microspheres
- PLA microspheres
- in-situ forming depot
- Atrigel
- FluidCrystal
- SmartDepot
- multivesicular liposomes
- DepoFoam
- BioSeizer
- thermo-responsive hydrogel
- RTGel
- liquid crystalline depot
- liquid crystal depot
- depot-forming prodrug
- depot prodrug
- long-acting prodrug
- long-acting emulsion
- Medisorb
- CriPec
- DiffuSphere
- PASylation
- site-specific PEGylation
- Fc fusion
- Fc-fusion
- IgG Fc fusion
- albumin binding
- albumin fusion
- albumin-binding
- lipidation
- fatty acid conjugation
- polypeptide extension
- glyco-engineering
- glycan engineering
- sialylation
- half-life extension

[DOSING INTERVALS - 14 patterns]
- once-monthly
- once-weekly injection
- once every 2 weeks
- once every 3 months
- once every 6 months
- q4w
- q8w
- q12w
- q2w
- 6-month
- 3-month
- quarterly injection
- biweekly injection
- monthly injection

[EXCLUSIONS - 21 terms]
- implantable device
- surgically implanted
- transdermal patch
- oral tablet
- oral capsule
- topical cream
- gene therapy
- cell therapy
- CAR-T
- vaccine
- vaccination
- prophylactic vaccine
- cosmetic
- veterinary
- diagnostic
- oral tablet
- oral capsule
- oral drug
- oral medication
- pill factory
- tablet manufacturing

=== END PROMPT ===
